Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
Teva Pharmaceuticals (NYSE:TEVA) just served up some serious growth numbers in its Q3 2024 report, turning heads with a $4.3 billion revenuea 13% boost from last year’s numbers. With its U.S. generics sales hitting over $1 billion and its key therapies like Austedo and the new schizophrenia treatment Uzedy soaring, Teva’s strategic pivot is clearly paying off. Generics rocketed to $2.5 billion globally, and the company now expects even more revenue from Uzedy, raising its full-year forecast for the therapy.
CEO Richard Francis calls this a clear win for Teva’s Pivot to Growth strategy, which is charging ahead by building both generics and high-potential new treatments. Teva’s development pipeline is stacked with fresh innovations,…
